Home
About
Overview
Sharing Data
ORCID
Help
History (19)
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.
N-Terminal Acetyltransferase D
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.
On Patient Safety: Is it Possible to Operate Too Much?
See All 19 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
On Patient Safety: Is it Possible to Operate Too Much?
On Patient Safety: Is it Possible to Operate Too Much? Clin Orthop Relat Res. 2017 12; 475(12):2858-2860.
View in:
PubMed
subject areas
Appointments and Schedules
Clinical Competence
Humans
Orthopedic Procedures
Orthopedic Surgeons
Patient Safety
Postoperative Complications
Risk Assessment
Risk Factors
Treatment Outcome
Workload
authors with profiles
Michael Jihoon Lee